Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Amortization of Deferred Charges (2016 - 2023)

Fortress Biotech (FBIO) has 9 years of Amortization of Deferred Charges data on record, last reported at $177000.0 in Q3 2023.

  • For Q3 2023, Amortization of Deferred Charges fell 11.94% year-over-year to $177000.0; the TTM value through Jun 2024 reached $177000.0, down 66.48%, while the annual FY2023 figure was $353000.0, 54.16% down from the prior year.
  • Amortization of Deferred Charges reached $177000.0 in Q3 2023 per FBIO's latest filing, up from $85000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $221000.0 in Q1 2021 and bottomed at $85000.0 in Q2 2023.
  • Average Amortization of Deferred Charges over 4 years is $173400.0, with a median of $177000.0 recorded in 2023.
  • Peak YoY movement for Amortization of Deferred Charges: surged 47.33% in 2021, then crashed 60.47% in 2023.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $205000.0 in 2020, then dropped by 19.51% to $165000.0 in 2021, then fell by 8.48% to $151000.0 in 2022, then rose by 17.22% to $177000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $177000.0 in Q3 2023, $85000.0 in Q2 2023, and $91000.0 in Q1 2023.